Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review

BackgroundHealth state utility values (HSUVs) are important in the assessment of the cost effectiveness of new interventions. In the case of visual conditions, models generally tend have tended to be built around a set of health states defined by visual acuity (VA). The aim of this review was to assess the impact of VA on HSUVs in patients with diabetic retinopathy, diabetic macular oedema or age-related macular degeneration.MethodsA systematic literature search was undertaken in major bibliographic databases to identify articles reporting on the relationship between HSUVs and vision. Data were extracted for population characteristics, visual levels and estimated utilities. Evidence from reported statistical models, where available, was considered in the evaluation of vision in the better-seeing eye and the worse-seeing eye. Due to the heterogeneity of included studies, a narrative synthesis was undertaken.ResultsOf the 17 relevant studies, 9 studies had data that could be used in the analysis of the impact of vision on HSUVs. Visual loss was associated with a marked impact on health utilities. However, the relationship was not comparable between conditions or by measure of HSUVs. Key results included the finding that overall, self-rated time-trade off estimates were more likely to discriminate between different VA levels than EQ-5D values. Additionally, a stronger correlation was observed between HSUVs and better-seeing eye VA compared to worse-seeing eye VA.ConclusionsVisual acuity has a significant impact on HSUVs. Nevertheless, care must be taken in the interpretation and use of estimates in cost-effectiveness models due to differences in measures and population diversity.

[1]  Emily Y. Chew,et al.  National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. , 2003 .

[2]  D. Fryback,et al.  Dollars May Not Buy as Many QALYs as We Think: , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  M. Gordon,et al.  The impact of anchor point on utilities for 5 common ophthalmic diseases. , 2008, Ophthalmology.

[4]  Julie Ratcliffe,et al.  Measuring and valuing health benefits for economic evaluation in adolescence: an assessment of the practicality and validity of the child health utility 9D in the Australian adolescent population. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  S. Bressler,et al.  National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. , 2003, Archives of ophthalmology.

[6]  T. Lim,et al.  Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population , 2012, Eye.

[7]  M. Barkham,et al.  Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). , 2012, Health technology assessment.

[8]  G. Torrance.  Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.

[9]  G W Torrance,et al.  Multi-attribute health status classification systems. Health Utilities Index. , 1995, PharmacoEconomics.

[10]  N. Bressler,et al.  Rasch analysis in the development of a simplified version of the national eye institute visual-function questionnaire-25 for utility estimation , 2012, Quality of Life Research.

[11]  Anthony J. Culyer,et al.  Health Utilities Index , 2014 .

[12]  R. Parrish,et al.  Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma. , 1997, Transactions of the American Ophthalmological Society.

[13]  Gisèle Soubrane,et al.  Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. , 2007, Archives of ophthalmology.

[14]  Utility values in Japanese patients with exudative age-related macular degeneration , 2011, Japanese Journal of Ophthalmology.

[15]  G. Brown,et al.  Utilities associated with diabetic retinopathy: results from a Canadian sample , 2003, The British journal of ophthalmology.

[16]  John Brazier,et al.  Valuing condition-specific health states using simulation contact lenses. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  R. Hays,et al.  Development of the 25-item National Eye Institute Visual Function Questionnaire. , 2001, Archives of ophthalmology.

[18]  G. Brown,et al.  Quality of life associated with unilateral and bilateral good vision. , 2001, Ophthalmology.

[19]  P. Buchholz,et al.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration , 2009, Clinical ophthalmology.

[20]  Kia-Chong Chua,et al.  Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation. , 2013, Health technology assessment.

[21]  P. Savino.  Optic neuritis treatment trial. , 1994, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[22]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[23]  Verteporfin photodynamic therapy cohort study: report 2: clinical measures of vision and health-related quality of life. , 2009, Ophthalmology.

[24]  Gary C. Brown,et al.  Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. , 2002, Archives of ophthalmology.

[25]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[26]  K. Boye,et al.  Health utility values associated with diabetic retinopathy , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[27]  M Sculpher,et al.  EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. , 2012, Health technology assessment.

[28]  E. Bass,et al.  Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1. , 2003, Archives of ophthalmology.

[29]  John Brazier,et al.  Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  G. Brown,et al.  Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients , 2002, The British journal of ophthalmology.

[31]  G. Brown,et al.  Vision and quality-of-life. , 1999, Transactions of the American Ophthalmological Society.

[32]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[33]  J. Sahel,et al.  Health-related quality of life and utility in patients with age-related macular degeneration. , 2007, Archives of ophthalmology.

[34]  R. Klein,et al.  The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. , 2001, Archives of ophthalmology.

[35]  P. Aspinall,et al.  Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration , 2007, British Journal of Ophthalmology.

[36]  Julie Ratcliffe,et al.  The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. , 2012, Investigative ophthalmology & visual science.

[37]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[38]  Gary C. Brown,et al.  A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes , 2004, International Ophthalmology.

[39]  Gary C. Brown,et al.  Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. , 2003, Ophthalmology.

[40]  J. Brazier,et al.  Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.

[41]  J. Brazier,et al.  Estimating a Preference-Based Index for a 5-Dimensional Health State Classification for Asthma Derived from the Asthma Quality of Life Questionnaire , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[42]  Carlo A Marra,et al.  Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients , 2006, Health and quality of life outcomes.

[43]  John Brazier,et al.  A Review of Generic Preference-Based Measures of Health-Related Quality of Life in Visual Disorders , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[44]  S. Gupta,et al.  TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD , 2004, Ophthalmic epidemiology.

[45]  S. Cole,et al.  The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. , 2000, Investigative ophthalmology & visual science.

[46]  J. Rudmin.  Calculating the Exact Pooled Variance , 2010, 1007.1012.

[47]  C. Carswell.  Measuring and Valuing Health Benefits for Economic Valuation , 2007, PharmacoEconomics.

[48]  Jill Carlton,et al.  The impact of age-related macular degeneration on health status utility values. , 2005, Investigative ophthalmology & visual science.